참고문헌
- Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al.; European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207. https://doi.org/10.1016/j.crohns.2014.04.005
- Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, et al. Canadian Association of Gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn's disease. Gastroenterology 2019;157:320-48. https://doi.org/10.1053/j.gastro.2019.03.022
- Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al.; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6. https://doi.org/10.1053/j.gastro.2006.12.003
- Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-74.e2. https://doi.org/10.1053/j.gastro.2012.04.046
- Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc 2016;104:240-3. https://doi.org/10.3163/1536-5050.104.3.014
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5:210. https://doi.org/10.1186/s13643-016-0384-4
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. https://doi.org/10.1186/1745-6215-8-16
- Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22. https://doi.org/10.1002/ibd.20845
- de Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011;33:243-50. https://doi.org/10.1111/j.1365-2036.2010.04507.x
- Gouldthorpe O, Catto-Smith AG, Alex G, Simpson D. Loss of response to long-term infliximab therapy in children with Crohn's disease. Pharmaceuticals (Basel) 2013;6:1322-34. https://doi.org/10.3390/ph6101322
- Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:606-13. https://doi.org/10.1097/MIB.0000000000000003
- Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1177-86. https://doi.org/10.1097/MIB.0000000000000083
- Grover Z, Biron R, Carman N, Lewindon P. Predictors of response to Infliximab in children with luminal Crohn's disease. J Crohn's Colitis 2014;8:739-46. https://doi.org/10.1016/j.crohns.2013.12.017
- Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease. Clin Gastroenterol Hepatol 2015;13:1748-56. https://doi.org/10.1016/j.cgh.2015.04.010
- Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab "top-down" strategy is superior to "step-up" in maintaining long-term remission in the treatment of pediatric crohn disease. J Pediatr Gastroenterol Nutr 2015;60:737-43. https://doi.org/10.1097/MPG.0000000000000711
- Dupont-Lucas C, Sternszus R, Ezri J, Leibovitch S, Gervais F, Amre D, et al. Identifying patients at high risk of loss of response to infliximab maintenance therapy in paediatric Crohn's disease. J Crohn's Colitis 2016;10:795-804. https://doi.org/10.1093/ecco-jcc/jjw038
- Cheng J, Hamilton Z, Smyth M, Barker C, Israel D, Jacobson K. Concomitant therapy with immunomodulator enhances infliximab durability in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2017;23:1762-73. https://doi.org/10.1097/MIB.0000000000001212
- deBruyn JC, Jacobson K, El-Matary W, Carroll M, Wine E, Wrobel I, et al. Long-term outcomes of infliximab use for pediatric Crohn disease: a canadian multicenter clinical practice experience. J Pediatr Gastroenterol Nutr 2018;66:268-73. https://doi.org/10.1097/MPG.0000000000001672
- Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9. https://doi.org/10.1038/ajg.2009.493
- Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, et al.; Dutch PIBD Working Group Kids with Crohn and Colitis. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr 2015;60:205-10. https://doi.org/10.1097/MPG.0000000000000589
- Li S, Reynaert C, Su AL, Sawh S. Efficacy and safety of infliximab in pediatric Crohn disease: a systematic review and meta-analysis. Can J Hosp Pharm 2019;72:227-38.
- Dziechciarz P, Horvath A, Kierkus J. Efficacy and safety of adalimumab for paediatric Crohn's disease: a systematic review. J Crohn's Colitis 2016;10:1237-44. https://doi.org/10.1093/ecco-jcc/jjw077
- Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring. Gastroenterology 2019;157:985-996.e2. https://doi.org/10.1053/j.gastro.2019.06.003
- Frymoyer A, Piester TL, Park KT. Infliximab dosing strategies and predicted trough exposure in children with Crohn disease. J Pediatr Gastroenterol Nutr 2016;62:723-7. https://doi.org/10.1097/MPG.0000000000001123
피인용 문헌
- Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient prefer vol.11, pp.11, 2020, https://doi.org/10.1136/bmjopen-2021-054154